Peripheral Arterial Disease (PAD) Drugs-United States Market Status and Trend Report 2013-2023
Report Summary
Peripheral Arterial Disease (PAD) Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Peripheral Arterial Disease (PAD) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Peripheral Arterial Disease (PAD) Drugs 2013-2017, and development forecast 2018-2023
Main market players of Peripheral Arterial Disease (PAD) Drugs in United States, with company and product introduction, position in the Peripheral Arterial Disease (PAD) Drugs market
Market status and development trend of Peripheral Arterial Disease (PAD) Drugs by types and applications
Cost and profit status of Peripheral Arterial Disease (PAD) Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Peripheral Arterial Disease (PAD) Drugs market as:
United States Peripheral Arterial Disease (PAD) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Peripheral Arterial Disease (PAD) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Others
United States Peripheral Arterial Disease (PAD) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
United States Peripheral Arterial Disease (PAD) Drugs Market: Players Segment Analysis (Company and Product introduction, Peripheral Arterial Disease (PAD) Drugs Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Peripheral Arterial Disease (PAD) Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Peripheral Arterial Disease (PAD) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole United States and Regional Market Size of Peripheral Arterial Disease (PAD) Drugs 2013-2017, and development forecast 2018-2023
Main market players of Peripheral Arterial Disease (PAD) Drugs in United States, with company and product introduction, position in the Peripheral Arterial Disease (PAD) Drugs market
Market status and development trend of Peripheral Arterial Disease (PAD) Drugs by types and applications
Cost and profit status of Peripheral Arterial Disease (PAD) Drugs, and marketing status
Market growth drivers and challenges
The report segments the United States Peripheral Arterial Disease (PAD) Drugs market as:
United States Peripheral Arterial Disease (PAD) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
New England
The Middle Atlantic
The Midwest
The West
The South
Southwest
United States Peripheral Arterial Disease (PAD) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Others
United States Peripheral Arterial Disease (PAD) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospitals
Clinics
Others
United States Peripheral Arterial Disease (PAD) Drugs Market: Players Segment Analysis (Company and Product introduction, Peripheral Arterial Disease (PAD) Drugs Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
1.1 Definition of Peripheral Arterial Disease (PAD) Drugs in This Report
1.2 Commercial Types of Peripheral Arterial Disease (PAD) Drugs
1.2.1 Clopidogrel (Plavix)
1.2.2 Prasugrel (Effient)
1.2.3 Ticagrelor (Brilinta)
1.2.4 Vorapaxar (Zontivity)
1.2.5 Others
1.3 Downstream Application of Peripheral Arterial Disease (PAD) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Peripheral Arterial Disease (PAD) Drugs
1.5 Market Status and Trend of Peripheral Arterial Disease (PAD) Drugs 2013-2023
1.5.1 United States Peripheral Arterial Disease (PAD) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Peripheral Arterial Disease (PAD) Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Peripheral Arterial Disease (PAD) Drugs in United States 2013-2017
2.2 Consumption Market of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.2.1 Consumption Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.2.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.3 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.3.1 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in New England 2013-2017
2.3.2 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The West 2013-2017
2.3.5 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The South 2013-2017
2.3.6 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in Southwest 2013-2017
2.4 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs in United States 2018-2023
2.4.1 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs in United States 2018-2023
2.4.2 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Types
3.1.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Peripheral Arterial Disease (PAD) Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Downstream Industry
4.2 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in New England
4.2.2 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The West
4.2.5 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The South
4.2.6 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in Southwest
4.3 Market Forecast of Peripheral Arterial Disease (PAD) Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 Peripheral Arterial Disease (PAD) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Major Players
6.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Major Players
6.3 Basic Information of Peripheral Arterial Disease (PAD) Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Peripheral Arterial Disease (PAD) Drugs Major Players
6.3.2 Employees and Revenue Level of Peripheral Arterial Disease (PAD) Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca Plc. (UK)
7.1.1 Company profile
7.1.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.1.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca Plc. (UK)
7.2 Bayer HealthCare Pharmaceuticals (Germany)
7.2.1 Company profile
7.2.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.2.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare Pharmaceuticals (Germany)
7.3 Bristol-Myers Squibb Company (US)
7.3.1 Company profile
7.3.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.3.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company (US)
7.4 Merck & Co., Inc. (US)
7.4.1 Company profile
7.4.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.4.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. (US)
7.5 Proteon Therapeutics, Inc. (US)
7.5.1 Company profile
7.5.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.5.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Proteon Therapeutics, Inc. (US)
7.6 Sanofi S.A. (France)
7.6.1 Company profile
7.6.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.6.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A. (France)
7.7 Symic Bio, Inc. (US)
7.7.1 Company profile
7.7.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.7.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Symic Bio, Inc. (US)
7.8 TheraVasc Inc. (US)
7.8.1 Company profile
7.8.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.8.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of TheraVasc Inc. (US)
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
8.1 Industry Chain of Peripheral Arterial Disease (PAD) Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
9.1 Cost Structure Analysis of Peripheral Arterial Disease (PAD) Drugs
9.2 Raw Materials Cost Analysis of Peripheral Arterial Disease (PAD) Drugs
9.3 Labor Cost Analysis of Peripheral Arterial Disease (PAD) Drugs
9.4 Manufacturing Expenses Analysis of Peripheral Arterial Disease (PAD) Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Peripheral Arterial Disease (PAD) Drugs in This Report
1.2 Commercial Types of Peripheral Arterial Disease (PAD) Drugs
1.2.1 Clopidogrel (Plavix)
1.2.2 Prasugrel (Effient)
1.2.3 Ticagrelor (Brilinta)
1.2.4 Vorapaxar (Zontivity)
1.2.5 Others
1.3 Downstream Application of Peripheral Arterial Disease (PAD) Drugs
1.3.1 Hospitals
1.3.2 Clinics
1.3.3 Others
1.4 Development History of Peripheral Arterial Disease (PAD) Drugs
1.5 Market Status and Trend of Peripheral Arterial Disease (PAD) Drugs 2013-2023
1.5.1 United States Peripheral Arterial Disease (PAD) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Peripheral Arterial Disease (PAD) Drugs Market Status and Trend 2013-2023
CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Peripheral Arterial Disease (PAD) Drugs in United States 2013-2017
2.2 Consumption Market of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.2.1 Consumption Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.2.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.3 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in United States by Regions
2.3.1 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in New England 2013-2017
2.3.2 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The Midwest 2013-2017
2.3.4 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The West 2013-2017
2.3.5 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in The South 2013-2017
2.3.6 Market Analysis of Peripheral Arterial Disease (PAD) Drugs in Southwest 2013-2017
2.4 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs in United States 2018-2023
2.4.1 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs in United States 2018-2023
2.4.2 Market Development Forecast of Peripheral Arterial Disease (PAD) Drugs by Regions 2018-2023
CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Types
3.1.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Peripheral Arterial Disease (PAD) Drugs in United States by Types
CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Downstream Industry
4.2 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in New England
4.2.2 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The Midwest
4.2.4 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The West
4.2.5 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in The South
4.2.6 Demand Volume of Peripheral Arterial Disease (PAD) Drugs by Downstream Industry in Southwest
4.3 Market Forecast of Peripheral Arterial Disease (PAD) Drugs in United States by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
5.1 United States Economy Situation and Trend Overview
5.2 Peripheral Arterial Disease (PAD) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES
6.1 Sales Volume of Peripheral Arterial Disease (PAD) Drugs in United States by Major Players
6.2 Revenue of Peripheral Arterial Disease (PAD) Drugs in United States by Major Players
6.3 Basic Information of Peripheral Arterial Disease (PAD) Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Peripheral Arterial Disease (PAD) Drugs Major Players
6.3.2 Employees and Revenue Level of Peripheral Arterial Disease (PAD) Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca Plc. (UK)
7.1.1 Company profile
7.1.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.1.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca Plc. (UK)
7.2 Bayer HealthCare Pharmaceuticals (Germany)
7.2.1 Company profile
7.2.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.2.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Bayer HealthCare Pharmaceuticals (Germany)
7.3 Bristol-Myers Squibb Company (US)
7.3.1 Company profile
7.3.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.3.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company (US)
7.4 Merck & Co., Inc. (US)
7.4.1 Company profile
7.4.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.4.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc. (US)
7.5 Proteon Therapeutics, Inc. (US)
7.5.1 Company profile
7.5.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.5.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Proteon Therapeutics, Inc. (US)
7.6 Sanofi S.A. (France)
7.6.1 Company profile
7.6.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.6.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A. (France)
7.7 Symic Bio, Inc. (US)
7.7.1 Company profile
7.7.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.7.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of Symic Bio, Inc. (US)
7.8 TheraVasc Inc. (US)
7.8.1 Company profile
7.8.2 Representative Peripheral Arterial Disease (PAD) Drugs Product
7.8.3 Peripheral Arterial Disease (PAD) Drugs Sales, Revenue, Price and Gross Margin of TheraVasc Inc. (US)
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
8.1 Industry Chain of Peripheral Arterial Disease (PAD) Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
9.1 Cost Structure Analysis of Peripheral Arterial Disease (PAD) Drugs
9.2 Raw Materials Cost Analysis of Peripheral Arterial Disease (PAD) Drugs
9.3 Labor Cost Analysis of Peripheral Arterial Disease (PAD) Drugs
9.4 Manufacturing Expenses Analysis of Peripheral Arterial Disease (PAD) Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF PERIPHERAL ARTERIAL DISEASE (PAD) DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
